Peanut allergy: Beyond the oral immunotherapy plateau
Clinical and Translational Allergy, 2021•Wiley Online Library
Background There are a lack of disease‐modifying treatments for peanut allergy, which is
lifelong in most instances. Oral immunotherapy has remained at the forefront of prospective
treatments, though its efficacy is consistently undermined by the risk of adverse reactions
and meager sustained effects. Aim This review discusses the current state of oral
immunotherapy, its strengths and limitations, and the future of therapeutics for the treatment
of peanut allergy. Conclusion The persistence of peanut allergy is currently attributed to …
lifelong in most instances. Oral immunotherapy has remained at the forefront of prospective
treatments, though its efficacy is consistently undermined by the risk of adverse reactions
and meager sustained effects. Aim This review discusses the current state of oral
immunotherapy, its strengths and limitations, and the future of therapeutics for the treatment
of peanut allergy. Conclusion The persistence of peanut allergy is currently attributed to …
Background
There are a lack of disease‐modifying treatments for peanut allergy, which is lifelong in most instances. Oral immunotherapy has remained at the forefront of prospective treatments, though its efficacy is consistently undermined by the risk of adverse reactions and meager sustained effects.
Aim
This review discusses the current state of oral immunotherapy, its strengths and limitations, and the future of therapeutics for the treatment of peanut allergy.
Conclusion
The persistence of peanut allergy is currently attributed to reservoirs of peanut‐specific memory B cells and Th2 cells, though the cellular and molecular interplay that facilitates the replenishment of peanut‐specific IgE remains elusive. Uncovering these events will prove critical for identification of novel targets as we forge ahead to a new age of peanut allergy treatment with biotherapeutics.
Wiley Online Library以上显示的是最相近的搜索结果。 查看全部搜索结果